NCT00418093 - Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

January 31, 2011

Study Completion Date

October 31, 2011

Conditions

Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer

Interventions

DRUG

Gemcitabine

Given intravenously over 30 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.

DRUG

Oxaliplatin

Given intravenously over 2 hours on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.

DRUG

Bevacizumab

Given intravenously over 30-90 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston